August brings a decade of expertise building high throughput automation, problem solving, and scaling teams at technology-driven biotechs. He was an early employee of Recursion where he scaled their high-content imaging platform by multiple orders of magnitude before joining Enveda in 2021. At Enveda, he is responsible for overseeing the company’s platform to annotate the structure and function of molecules from the natural world to discover new medicines. Outside of work, August enjoys soccer, reading, skiing, and losing to Viswa at all kinds of racquet sports.

Bigyan comes to Enveda with >15 years of experience in scientific research, strategy consulting and investment analysis, with roles at NYU Smilow Cancer Center, Clarion Healthcare, AstraZeneca, and Rock Springs Capital. At Rock Springs, he evaluated 600+ biotech companies, investing in 30+ and supporting 7 exits. At AstraZeneca, Bigyan built business cases to guide go/no-go decisions and collaborated with the oncology BD team. Bigyan holds a PhD in Cancer Biology from MIT and graduated summa cum laude from Saint Peter’s University, NJ. Outside of work, he enjoys road trips, national parks, alumni activities for both Saint Peter’s and MIT, engagements with Nepali scientists and entrepreneurs, and reruns of “Curb Your Enthusiasm” seeing himself in Larry David to his wife’s dismay.

Dan has been with the company since before the seed round, leading Finance, Legal, Quality, SynBio, and Special Projects. With over 10 years of experience in building products and leading companies, he bridges the science, buisness and operations to make sure Enveda is running as fast as we can reliably and safely. Dan earned his PhD in Molecular Biology and has several publications in high-impact journals. Prior to joining Enveda, Dan, founded and led as CEO a synthetic biology company focused on scalable and cost-effective biologics manufacturing for large pharmaceutical companies, which was later acquired by Vectron Biosolutions. Outside of work, Dan enjoys spending time with his family, cooking, playing music, skiing and random walks.

Eswar Sunil Kumar Bonangi has over a decade of extensive experience in consulting, strategy, and operations across diverse sectors, including power, mining, and government services. Eswar joined Enveda in 2021 and is the Vice President and Head of Operations at Enveda’s state-of-the-art facility located in Genome Valley, Hyderabad. Prior to joining Enveda, he worked with KPMG where his key contributions included leading the rollout of World Bank-funded AMI solutions in Andhra Pradesh, supporting policy formulation and implementing large scale government programs. Eswar has a MBA from the Indian Institute of Management, Tiruchirappalli, and a Bachelor of Technology degree in Biotechnology from GITAM. Eswar is a passionate photographer, capturing the world through his lenses and finding inspiration in every frame and every human.

Hannah Gordon brings extensive expertise in translational biology and strategic drug discovery. With over a decade in biotech, including at Recursion, Hannah has become a leader in leveraging cutting-edge technologies for drug discovery. She excels at transforming complex scientific concepts into actionable processes, fostering cross-functional collaboration, and driving progress in translating nature into medicine. Her blend of molecular biology expertise and commercial acumen makes her a key innovator, continually pushing boundaries in drug discovery and development. She holds a Ph.D. in Human Genetics, and an HHMI-sponsored MS in Clinical Investigation from the University of Utah. When Hannah is not chasing her curiosities, she can be found adventuring in the Rockies with her partner Tyson and dog Carbon.

Inhwan Kim has diverse experience across provider, payor, and investor roles, which provides him with a unique cross-functional perspective at the intersection of science, finance, and healthcare strategy. Most recently, he managed the portfolio at BridgeBio, where he prioritized investments and ensured cohesive strategies across multiple drug development initiatives. Previously, he served as a consultant at McKinsey & Company, advising biotechs, pharmaceutical firms and global health authorities. Inhwan holds a Pharm.D. from Rutgers University and an MBA in Finance and Healthcare Management from The Kellogg School of Management at Northwestern University. Outside of work, he finds joy in daily walks with his wife Julie (and her dog Lulu).

Jason is a licensed Attorney at Law and a Registered U.S. Patent Attorney. As a former chemist who transitioned from research to law, he built a diverse career with over a decade of experience in private practice where he advised clients ranging from startups to multinational corporations on managing complex legal issues and scaling their competitiveness. Jason holds degrees in biochemistry, chemistry, and law, and is currently a Ph.D. candidate in bioinformatics. Jason also serves as a visiting lecturer at Harvard Medical School and a visiting professor at Michigan State University Law School, where he teaches on innovation and related topics. Outside of work, Jason is found playing board games with his family and volunteering at his kids’ school.

Dr. José Miguel Trevejo is a physician-scientist and biotechnology executive who has led organizations in the development of high impact medicines spanning multiple therapeutic areas and modalities. Prior to Enveda he was the CMO of Tarsus Pharma where he helped lead the FDA approval and successful launch of a novel category-creating ophthalmology therapy. Dr. Trevejo also served as CDO for Rocket Pharmaceuticals and CEO of the non-viral gene therapy company SmartPharm, which was acquired in 2020. Prior to SmartPharm, he held increasing roles of responsibility at Ironwood, Genentech and Vertex Pharmaceuticals. Dr. Trevejo received his MD and PhD at the Cornell-Rockefeller-Sloan Kettering Tri-Institutional MD/PhD Program and completed his residency and specialty training at Harvard Medical School affiliates BWH and BIDMC. Outside of work he enjoys traveling the world with his wife and two teenage boys, cooking, jazz music, tennis and personal growth.

Niranjan Rao has deep global drug development experience as a senior executive in biotech and global pharmaceutical companies and in leading teams from discovery through NDA across therapeutic areas. His most recent position was as Senior Vice-President of Development Sciences at Asana BioSciences where he built a high performance development organization that filed 7 INDs in 5 years and took multiple molecules to POC and beyond. He has lead clinical pharmacology teams at Endo Pharmaceuticals, Kyowa Hakko Kirin Pharma, Forest Laboratories, and Aventis Pharmaceuticals. He is a clinical pharmacologist by training and a Fellow of the American College of Clinical Pharmacology. When not at his desk, Niranjan dabbles in photography, loves tending to his herb and vegetable garden and reading.

Prabhakar K (PK) Jadhav is a seasoned executive who has made major contributions to more than 25 clinical candidates, including several to Enveda’s deep pipeline, as a drug designer and molecular architect. His prior experience includes being the Director of Medicinal Chemistry at DuPont Pharmaceuticals, Senior Research Fellow at Eli Lilly, and Co-Founder & SVP Medicinal Chemistry at Minghui Pharma. PK obtained his PhD in organic synthesis from National Chemical Laboratory, Pune, India and worked with Nobel Laureate Herbert C. Brown during his postdoctoral training. When PK is not thinking of drug discovery, he likes to walk or trek with his wife Meera in California, Arizona, or Sahyadri Mountains in India.

Robert brings over 20 years of human resources experience, most recently serving as Chief People Officer at Rainfocus, a Series C startup, where he built a global-scale workforce and helped the company achieve a Top 5 workplace ranking in Utah. Prior to that, at Thumbtack, he oversaw more than 700 global staff, while guiding the company to become the best place to work in Utah. His extensive HR management experience also includes overseeing over 6,000 people across APAC, EU, and North America as Director of HR at eBay and as VP of HR at GE Healthcare. Robert holds an MBA from Rensselaer Polytechnic Institute. Outside of work, Robert spends time with his family and follows ‘the beautiful game’ (soccer).

Soum leads our Corporate Development and Investor Relations team. Prior to Enveda, he was a member of the healthcare investment banking team at Goldman Sachs, where he focused on M&A, equity financings, and strategic alternatives for both public and private healthcare clients. During his time there, he advised companies across biopharma, diagnostics, and hospital systems, executing over $5 billion in M&A and partnership transactions, over $1 billion in financings and gathering a lifetime of “almost-deals” along the way. Prior to that, Soum spent several years as a strategy consultant at Monitor Group in their Singapore office, advising clients across Asia in government, financial services and telecom on a wide range of strategic engagements. Soum received his MBA with a major in finance from the Kellogg School of Management at Northwestern University and his BS in electrical and electronic engineering from Nanyang Technological University in Singapore. Outside of work, Soum can be found exploring new hiking trails in the Bay Area, discovering craft beers and keeping up with Steph Curry’s latest on the court.

Tendai leads Enveda’s sustainability and global health strategic initiatives with national and foreign governments, global environmental organizations and NGOs including the Bill and Melinda Gates Foundation. Previously, Tendai was a biotech investor at Hummingbird Ventures, harboring a high conviction, low frequency investment philosophy deploying checks up to $10M in the next generation of life sciences founders in the US and EU. Tendai holds a PhD in Clinical Biochemistry from the University of Cambridge, England, where she attended with a full scholarship as a Herchel Smith Scholar and graduated from Williams College, MA with a double major in Chemistry and Biology, and has 10+ years of scientific research experience ranging from infectious disease and obesity to pulmonary disease and schizophrenia, from leading institutes including the Broad Institute of MIT and Harvard and Johns Hopkins Hospital. Outside of work, Tendai enjoys intramural sports, reading foreign fiction and Biblical literature, and helping early stage founders hone their business ideas.

Viswa brings over a decade of experience in translational biomedical discovery across biotech and research. He previously served as the first Innovation Scientist and Product Manager at Recursion, where he also established the Portfolio/Early Commercial team. Viswa holds the distinction of being the youngest PhD graduate from UW Madison’s CMB Class of 2011, where he developed novel candidate immunotherapies. Viswa was named a UBS Global Visionary in 2023, and serves on the World Economic Forum’s Unicorn Innovator Community. In his spare time, Viswa enjoys playing and watching raquet sports of all kinds, trying to read several books in parallel, and traveling with his wife Haliee.